Pair page
Ipamorelin with Sermorelin
Mechanism-tag overlap and published literature for Ipamorelin and Sermorelin, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
growth-hormone-secretagogueselective-ghrelin-receptor-agonist
ghrh-analog-growth-hormone-secretagogue
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Ipamorelin and Sermorelin have published these mechanism-level observations. Not a co-administration recommendation.
The most common sermorelin pairing. Different receptor (GHSR-1a vs GHRH-R) with synergistic GH-pulse effect. Standard "GHRH + GHRP" stack in wellness-clinic practice — usually dosed together at bedtime. Produces larger GH pulse than either alone without meaningful cortisol/prolactin elevation.
Quick facts
Ipamorelin
Sermorelin
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2014 | Ipamorelin | Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. PMID: 2… PMID 25331030 | human trial |
| — | Ipamorelin | ClinicalTrials.gov. Study of IPAMORELIN on the Management of Postoperative Ileus Following Partial Bowel Resection. NCT00672074. | human trial |
| 2008 | Ipamorelin | Veldhuis JD, Keenan DM. Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men. Eur J Endocrinol. 2008;159(5):547-554. PMID: 18728125. PMID 18728125 | human study |
| 2008 | Ipamorelin | Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. PMID: 18981485. (MK-677 comparator data.) PMID 18981485 | human study |
| 2001 | Ipamorelin | Ghigo E, Arvat E, Giordano R, et al. Biologic activities of growth hormone secretagogues in humans. Endocrine. 2001;14(1):87-93. PMID: 11322506. PMID 11322506 | human study |
| 1999 | Ipamorelin | Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PMID: 10496658. PMID 10496658 | human study |
| 2012 | Ipamorelin | Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012;4:149-155. PMID: 27186126. PMID 27186126 | preclinical, in vivo |
| 2000 | Ipamorelin | Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-577. PMID: 10828840. PMID 10828840 | preclinical, in vivo |
| 2020 | Ipamorelin | Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. doi: 10.1002/rco2.9. | mechanism / discovery |
| 1998 | Ipamorelin | Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822. (The foundational discovery paper; establishes the selectivity claim.) PMID 9849822 | mechanism / discovery |
| 2026 | Ipamorelin | World Anti-Doping Agency. The 2026 Prohibited List. Section S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org. | regulatory / registry |
| 2025 | Ipamorelin | U.S. Food and Drug Administration. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| 2012 | Sermorelin | Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429.… PMID 22869065 | human study |
| 1999 | Sermorelin | Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PMID: 18031173. PMID 18031173 | human study |
| 1996 | Sermorelin | Ghigo E, Aimaretti G, Gianotti L, Bellone J, Arvat E, Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol. 1996;134(3):352-356. PMID: 8616536. PMID 8616536 | human study |
| 2020 | Sermorelin | Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. | mechanism / discovery |
| 2025 | Sermorelin | WADA. 2025 Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. | regulatory / registry |
| 2006 | Sermorelin | Walker RF. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. PMID: 18046908. PMC2699646. PMID 18046908 | research article |
| 2003 | Sermorelin | Merriam GR, Schwartz RS, Vitiello MV. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003;22(1):41-48. PMID: 14662999. PMID 14662999 | research article |
| 1997 | Sermorelin | Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in older men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PMID: 9141535. PMID 9141535 | research article |
| 1996 | Sermorelin | Thorner M, Rochiccioli P, Colle M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-1196. PM… PMID 8772599 | research article |
| 1992 | Sermorelin | Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. PMID: 1379256. PMID 1379256 | research article |
| 1992 | Sermorelin | Duck SC, Schwarz HP, Costin G, et al. Subcutaneous growth hormone-releasing hormone therapy in growth hormone-deficient children: first year of therapy. J Clin Endocrinol Metab. 1992;75(4):1115-1120. PMID: 1400880. PMID 1400880 | research article |
| 1985 | Sermorelin | Vance ML, Kaiser DL, Evans WS, et al. Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor. Evidence for intermittent somatostatin secretion. J Clin Invest. 1985;75(5):1584-1590. PMID: 2860118. PMID 2860118 | research article |
Related pair pages
More research context
Frequently asked
Have Ipamorelin and Sermorelin been studied together?
Researchers have published mechanistic-level co-administration discussion of Ipamorelin and Sermorelin. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Ipamorelin and Sermorelin share?
Ipamorelin and Sermorelin do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Ipamorelin and Sermorelin?
Ipamorelin: Not approved. Sermorelin: Approved 1997; discontinued 2008 (commercial). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Ipamorelin and Sermorelin?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Ipamorelin profile and the Sermorelin profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026